ResearcherHokkaido UniversityActive in the last 2 years

Naoya Sakamoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6273-0189; OpenAlex author ID A5003268449. Sources: OpenAlex.

Their work

Papers: 4 (first author 0, last author 4)
Trials: 0
Grants: 0
Labs led: 2
Collaborators: 11

Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 2 papers

Papers 4

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Kazuaki Harada · 2 shared papers, 2021–2025 · strength 0.38
- Paper Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic d… DOI 10.1007/s00432-025-06216-8 ↗
- Paper Comparison of FOLFIRINOX, Gemcitabine Plus Nab-Paclitaxel, and Chemoradiotherapy as First-Line Treatments for Locally A… DOI 10.21203/rs.3.rs-356113/v1 ↗
Yoshito Komatsu · 2 shared papers, 2021–2025 · strength 0.38
- Paper Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic d… DOI 10.1007/s00432-025-06216-8 ↗
- Paper Comparison of FOLFIRINOX, Gemcitabine Plus Nab-Paclitaxel, and Chemoradiotherapy as First-Line Treatments for Locally A… DOI 10.21203/rs.3.rs-356113/v1 ↗
Masaki Kuwatani · 2 shared papers, 2013–2025 · strength 0.34
- Paper Treatment of Pancreatic Cancer Using Near-Infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts in Combin… DOI 10.3390/cancers17091584 ↗
- Paper Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable p… DOI 10.1038/bjc.2013.108 ↗
Hiroki Yonemura · 1 shared paper, 2025 · strength 0.30
- Paper Treatment of Pancreatic Cancer Using Near-Infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts in Combin… DOI 10.3390/cancers17091584 ↗
Atsushi Masamune · 1 shared paper, 2025 · strength 0.30
- Paper Treatment of Pancreatic Cancer Using Near-Infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts in Combin… DOI 10.3390/cancers17091584 ↗
Takeaki Nakamura · 1 shared paper, 2025 · strength 0.25
- Paper Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic d… DOI 10.1007/s00432-025-06216-8 ↗
Shintaro Nakano · 1 shared paper, 2021 · strength 0.13
- Paper Comparison of FOLFIRINOX, Gemcitabine Plus Nab-Paclitaxel, and Chemoradiotherapy as First-Line Treatments for Locally A… DOI 10.21203/rs.3.rs-356113/v1 ↗
Yasuyuki Kawamoto · 1 shared paper, 2021 · strength 0.13
- Paper Comparison of FOLFIRINOX, Gemcitabine Plus Nab-Paclitaxel, and Chemoradiotherapy as First-Line Treatments for Locally A… DOI 10.21203/rs.3.rs-356113/v1 ↗
Kazunori Eto · 1 shared paper, 2013 · strength 0.03
- Paper Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable p… DOI 10.1038/bjc.2013.108 ↗
Taiki Kudo · 1 shared paper, 2013 · strength 0.03
- Paper Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable p… DOI 10.1038/bjc.2013.108 ↗
Akira Takasawa · 1 shared paper, 2013 · strength 0.03
- Paper Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable p… DOI 10.1038/bjc.2013.108 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.